\nArticle L233-8-II of the French Commercial Code\n
TOULOUSE, France--(BUSINESS WIRE)--Regulatory News:<\/p>
\nABIONYX Pharma (Paris:ABNX):<\/p>
\nMarket: Euronext Paris, Compartment C\n
\nDate<\/p><\/td> | \nNumber of shares outstanding<\/p><\/td> | \nTotal voting rights<\/p><\/td><\/tr>\n | |||
\nTotal gross (1)<\/sup><\/p><\/td> \nTotal net (2)<\/sup><\/p><\/td><\/tr>\n \nApril 30, 2026<\/p><\/td> \n35,511,655<\/p><\/td> \n45,235,726<\/p><\/td> \n44,998,754<\/p><\/td><\/tr>\n<\/table> \n(1) <\/sup>The total number of gross (or \u201ctheoretical\u201d) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.<\/p> \n(2) <\/sup>The total number of net (or \u201cexercisable at a Shareholders\u2019 Meeting\u201d) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the recommendation made by the AMF on 17 July 2007.<\/p> \nAbout ABIONYX Pharma<\/b><\/p> \nABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines in diseases where there is no effective or existing treatment, even the rarest ones. The company expedites the development of novel therapeutics through an extensive expertise in lipid science and a differentiated apoA-I -based technology platform. ABIONYX Pharma is committed to radically improving treatment outcomes in sepsis and critical care.<\/p> |